Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 6 May 2019 |
| ORION CORPORATION: ACQUISITION OF OWN SHARES 06.05.2019 | 6 May 2019 |
| ORION CORPORATION: ACQUISITION OF OWN SHARES 03.05.2019 | 3 May 2019 |
| ORION CORPORATION: ACQUISITION OF OWN SHARES 02.05.2019 | 2 May 2019 |
| Orion Group Interim Report January-March 2019 | 25 Apr 2019 |